Russell Sean

𝗣𝗵𝗮𝗿𝗺𝗮'𝘀 𝗠𝘂𝘀𝗶𝗰𝗮𝗹 𝗖𝗵𝗮𝗶𝗿𝘀 𝗖𝗵𝗮𝗻𝗴𝗲 𝗡𝗼𝘁𝗵𝗶𝗻𝗴 New faces, same incentives. The pharmaceutical industry reshuffles its executives constantly, and chronic disease rates keep climbing. ⬩ The people change. The business model doesn't. Patents, not cures, remain the product. ⬩ No executive reshuffle will fix a system that profits from management, not resolution, of disease. When was the last time a pharma leadership change actually improved public health outcomes, rather than shareholder returns?

@Hsbmufc @GeoffShreeves Oh how delusional you are

@GeoffShreeves Bruno is just on a different level to Declan Rice and if you can’t see that then football really isn’t for you.

Declan Rice has won more games this season than Bruno Fernandes has played in.

WHAT IS GOING ON? How can a serial loser this season beat a man who has driven Arsenal to our first League title in 22 years? This is complete madness.

Coders aren't being replaced. They're being promoted to architects who review AI output. The developers who understand what's happening under the hood will own the next decade. Are you learning the scaffolding, or just trusting the black box?

⬩ The real question is who controls the scaffolding layer, not which LLM sits inside it ⬩ Alibaba's Qwen3 team is building equivalent agentic tooling, open source, at a fraction of the price ⬩ When the scaffolding commoditises, closed model providers lose their leverage entirely

𝗔𝗻𝘁𝗵𝗿𝗼𝗽𝗶𝗰'𝘀 𝗖𝗼𝗱𝗶𝗻𝗴 𝗘𝘃𝗲𝗻𝘁 𝗠𝗶𝘀𝘀𝗲𝗱 𝗧𝗵𝗲 𝗥𝗲𝗮𝗹 𝗦𝘁𝗼𝗿𝘆 At Anthropic's "Code with Claude" event in London, developers raised hands when asked who'd shipped pull requests written entirely by AI. The story everyone's filing is "AI is replacing coders." That framing is wrong.

Filed under: the compliance theatre. The question governments should be answering isn't "how much are we spending?" It's "what happens to our RSA-encrypted defence networks if this money arrives three years too late?" If your threat model assumes Q-Day is a decade away, is that assumption written down anywhere?

The tension nobody's naming: ⬩ Letters of intent are not contracts. The gap between a signed LoI and a funded, delivered system is where most government tech programmes quietly expire. ⬩ Quantinuum and PsiQuantum are pursuing fundamentally different architectures. Funding both hedges the bet but dilutes the focus. ⬩ GlobalFoundries entering quantum manufacturing is the genuinely underreported piece: you cannot scale fault-tolerant systems without specialist fabrication. That's the real infrastructure play here.

𝗨𝗦 𝗚𝗼𝘃𝗲𝗿𝗻𝗺𝗲𝗻𝘁 𝗝𝘂𝘀𝘁 𝗕𝗲𝘁 $𝟮𝗕 𝗼𝗻 𝗤𝘂𝗮𝗻𝘁𝘂𝗺. 𝗦𝗺𝗮𝗿𝘁 𝗼𝗿 𝗗𝗲𝘀𝗽𝗲𝗿𝗮𝘁𝗲? The Department of Commerce just signed letters of intent with 9 quantum companies, $2.013 billion in CHIPS Act incentives: Quantinuum for fault-tolerant trapped-ion machines, PsiQuantum for $100M in photonic silicon, GlobalFoundries launching a quantum manufacturing unit. The structure is notable.

𝗔𝗹𝗶𝗯𝗮𝗯𝗮'𝘀 𝗤𝘄𝗲𝗻 𝗝𝘂𝘀𝘁 𝗥𝗲𝘄𝗿𝗼𝘁𝗲 𝗔𝗴𝗲𝗻𝘁𝗶𝗰 𝗔𝗜'𝘀 𝗥𝘂𝗹𝗲𝘀 Qwen3.7 Max ran autonomously for 35 hours, made 1,158 tool calls, and achieved a 10x speed improvement on an attention kernel — through nothing more than compile, profile, rewrite, repeat. The mainstream narrative says the West leads on AI reasoning. China leads on AI doing. If agentic capability generalises across tasks the same way language does across text, the architecture race is already secondary. What's your ceiling for autonomous runtime before you'd trust a model unsupervised?

𝗢𝗽𝗲𝗻𝗔𝗜'𝘀 𝗜𝗣𝗢 𝗜𝘀 𝗮 𝗪𝗮𝗿𝗻𝗶𝗻𝗴 𝗦𝗶𝗴𝗻 @OpenAI is rushing to IPO in September while missing internal revenue KPIs, burning through data centre costs, and losing corporate ground to @AnthropicAI. Sam Altman is moving fast because the window won't stay open — not because the business is ready. If the fundamentals were strong, the CFO wouldn't need more time. Would you invest in a company racing to list before it can explain its own business model?

$1.8 billion chasing molecular tweaks while most people age faster than their grandparents did on simpler food, more sunlight, and less artificial light after dark. If the answer to longevity is already in your environment, who benefits from making it a patented molecule instead?

⬩ Retro's core focus is autophagy and partial reprogramming, tools that reset cellular age markers ⬩ What they don't address: the photonic and magnetic environment the cell operates in, which determines whether reprogramming signals are even read correctly ⬩ A reprogrammed cell in a broken light environment is a new engine in a flooded garage

𝗦𝗮𝗺 𝗔𝗹𝘁𝗺𝗮𝗻'𝘀 $𝟭.𝟴𝗕 𝗟𝗼𝗻𝗴𝗲𝘃𝗶𝘁𝘆 𝗕𝗲𝘁 𝗜𝘀 𝗔𝘀𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗪𝗿𝗼𝗻𝗴 𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻 Retro Biosciences just closed a new round valuing it at $1.8 billion. Sam Altman's bet: engineer longer life through cellular reprogramming. The science is real. The framing is wrong. They're treating ageing as a software bug when it's a hardware mismatch.

The deeper problem: chronic disease drugs are designed to be taken indefinitely, so high prices compound over a lifetime. Fixing root dysfunction through circadian biology, mitochondrial health, and food quality would collapse that revenue model entirely. Which is why nobody in power talks about it. If a governor won't allow a panel that can't even set prices, what would it actually take to get drug costs on the table?

⬩ The US pays 2.56x what Germany pays for the same branded drugs, per a 2024 RAND Corporation analysis ⬩ Advisory panels work: Australia's Pharmaceutical Benefits Advisory Committee has held drug prices stable for decades using exactly this model ⬩ The gap between what a drug costs to manufacture and what Americans pay at the pharmacy isn't a market outcome. It's a policy choice.

𝗩𝗶𝗿𝗴𝗶𝗻𝗶𝗮'𝘀 𝗚𝗼𝘃𝗲𝗿𝗻𝗼𝗿 𝗝𝘂𝘀𝘁 𝗣𝗿𝗼𝘁𝗲𝗰𝘁𝗲𝗱 𝗣𝗵𝗮𝗿𝗺𝗮, 𝗡𝗼𝘁 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 Virginia's Governor Glenn Youngkin vetoed a bill that would have created an advisory panel to review prescription drug pricing. Not a price cap. Not a mandate. An advisory panel. He blocked even that.